Zhao Fengping, Yu Zhenming, Tian Wei, Huang Xinhui, Zhang Qingsen, Zhou Ruolan, Hu Jian, Yu Shichong, Chen Xin, Zheng Canhui
School of Life Science and Technology, Wuhan Polytechnic University, Wuhan 430023, China.
The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai 200433, China.
Molecules. 2025 Jul 10;30(14):2924. doi: 10.3390/molecules30142924.
Stroke poses a serious threat to human health, while there are very few drugs that can directly alleviate ischemia/reperfusion injury and improve the prognosis. Studies have shown that small-molecule activators of aldehyde dehydrogenase 2 (ALDH2) have the potential to become novel therapeutic drugs for ischemic stroke. In this study, through the systematic structural optimization of novel -benzylaniline-based ALDH2 activators obtained from our previous virtual screening, ALDH2 activators with improved water solubility and activity were obtained. Among them, compound exhibits the best activity, with a maximum activation fold reaching 114% relative to Alda-1. And the water solubility of its hydrochloride salt was increased by more than 200-fold. The intravenous injection of this compound can significantly reduce the infarct area in the rat model of cerebral infarction compared with the model group. This study lays a good foundation for the future research on ALDH2 activators used in the treatment of stroke.
中风对人类健康构成严重威胁,而能够直接减轻缺血/再灌注损伤并改善预后的药物却非常少。研究表明,醛脱氢酶2(ALDH2)的小分子激活剂有潜力成为缺血性中风的新型治疗药物。在本研究中,通过对我们之前虚拟筛选得到的新型苄基苯胺类ALDH2激活剂进行系统的结构优化,获得了水溶性和活性均有所提高的ALDH2激活剂。其中,化合物表现出最佳活性,相对于Alda-1,最大激活倍数达到114%。其盐酸盐的水溶性增加了200多倍。与模型组相比,静脉注射该化合物可显著减小大鼠脑梗死模型中的梗死面积。本研究为未来用于治疗中风的ALDH2激活剂的研究奠定了良好基础。